Navigation Links
Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Date:10/20/2008

CAMBRIDGE, Mass., Oct. 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the third quarter of 2008 on Thursday, October 30, 2008 after the U.S. financial markets close.

In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Thursday, October 30, 2008 to discuss the company's financial results for the third quarter of 2008 and to provide an update on the company's discovery and development programs.

To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 69258196 or to listen to a live audio webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. A replay of the call will also be available from 7:30 p.m. ET on October 30, 2008 until November 13, 2008 11:59 p.m. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 69258196. An archived webcast will also be available for two weeks after the call on the Idenix website.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Amy Sullivan (617) 995-9901


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
2. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
3. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
4. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
8. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
9. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
10. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
11. GSK Notice of Third Quarter 2008 Results Announcement and Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 2Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 3Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 4Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 5Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 6Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 7Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 8Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 9Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 10Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 11Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 12Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 13Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 14Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 15Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History 16Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements 2Genta Incorporated to Present at the BIO CEO & Investor Conference 2Genta Incorporated to Present at the BIO CEO & Investor Conference 3
Breaking Biology News(10 mins):ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 2Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 1U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 2U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 3U S Food And Drug Administration 28FDA 29 Grants Traditional Approval for INTELENCE 28R 29 28etravirine 29 6543 4Hormone ghrelin can boost resistance to Parkinsons disease 10903 1Hormone ghrelin can boost resistance to Parkinsons disease 10903 2Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 1Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 2Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 3Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 4Elluminate 26apos 3Bs Fire and Ice Project Recognized as First Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 62141 5